TY - JOUR
T1 - Bacterial secretion of soluble and functional trivalent scFv-based N-terminal trimerbodies
AU - Blanco-Toribio, Ana
AU - Álvarez-Cienfuegos, Ana
AU - Sainz-Pastor, Noelia
AU - Merino, Nekane
AU - Compte, Marta
AU - Sanz, Laura
AU - Blanco, Francisco J.
AU - Álvarez-Vallina, Luis
N1 - Publisher Copyright:
© 2015, Blanco-Toribio et al.
PY - 2015/12/7
Y1 - 2015/12/7
N2 - Recombinant antibodies are used with great success in many different diagnostic and therapeutic applications. A variety of protein expression systems are available, but nowadays almost all therapeutic antibodies are produced in mammalian cell lines due to their complex structure and glycosylation requirements. However, production of clinical-grade antibodies in mammalian cells is very expensive and time-consuming. On the other hand, Escherichia coli (E. coli) is known to be the simplest, fastest and most cost-effective recombinant expression system, which usually achieves higher protein yields than mammalian cells. Indeed, it is one of the most popular host in the industry for the expression of recombinant proteins. In this work, a trivalent single-chain fragment variable (scFv)-based N-terminal trimerbody, specific for native laminin-111, was expressed in human embryonic kidney 293 cells and in E. coli. Mammalian and bacterially produced anti-laminin trimerbody molecules display comparable functional and structural properties, although importantly the yield of trimerbody expressed in E. coli was considerably higher than in human cells. These results demonstrated that E. coli is a versatile and efficient expression system for multivalent trimerbody-based molecules that is suitable for their industrial production.
AB - Recombinant antibodies are used with great success in many different diagnostic and therapeutic applications. A variety of protein expression systems are available, but nowadays almost all therapeutic antibodies are produced in mammalian cell lines due to their complex structure and glycosylation requirements. However, production of clinical-grade antibodies in mammalian cells is very expensive and time-consuming. On the other hand, Escherichia coli (E. coli) is known to be the simplest, fastest and most cost-effective recombinant expression system, which usually achieves higher protein yields than mammalian cells. Indeed, it is one of the most popular host in the industry for the expression of recombinant proteins. In this work, a trivalent single-chain fragment variable (scFv)-based N-terminal trimerbody, specific for native laminin-111, was expressed in human embryonic kidney 293 cells and in E. coli. Mammalian and bacterially produced anti-laminin trimerbody molecules display comparable functional and structural properties, although importantly the yield of trimerbody expressed in E. coli was considerably higher than in human cells. These results demonstrated that E. coli is a versatile and efficient expression system for multivalent trimerbody-based molecules that is suitable for their industrial production.
KW - E. coli
KW - Multivalent antibody
KW - Recombinant antibody
KW - Trimerbody
UR - http://www.scopus.com/inward/record.url?scp=84938578664&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84938578664&partnerID=8YFLogxK
U2 - 10.1186/s13568-015-0137-0
DO - 10.1186/s13568-015-0137-0
M3 - Article
C2 - 26239030
AN - SCOPUS:84938578664
SN - 2191-0855
VL - 5
JO - AMB Express
JF - AMB Express
IS - 1
M1 - 45
ER -